[1] Krebs S, et al. Comparison of68Ga-DOTA-JR11 PET/CT with dosimetric177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3047-3057. DOI:
10.1007/s00259-020-04832-9[2] Xie Q, et al. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3129-3140. DOI:
10.1007/s00259-021-05249-8